BiondVax

This article contains promotional content. Please help improve it by removing promotional language and inappropriate external links, and by adding encyclopedic text written from a neutral point of view. (August 2023) (Learn how and when to remove this message)

This article does not cite any sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "BiondVax" – news · newspapers · books · scholar · JSTOR (August 2023) (Learn how and when to remove this message)

BiondVax Pharmaceuticals Ltd.

Company type	Public
Traded as	Nasdaq: BVXV
Industry	Pharmaceuticals
Founded	2003; 21 years ago (2003)
Headquarters	Jerusalem , Israel
Number of employees	30 (2022)
Website	www.biondvax.com

BiondVax Pharmaceuticals Ltd. is an Israeli biopharmaceutical company focused on developing and manufacturing immunotherapeutic products, primarily for the treatment of infectious diseases and autoimmune diseases.

In collaboration with the Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax develops nanosized antibody (NanoAb) therapies for diseases such as COVID-19, asthma and psoriasis.

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and owns and operates a biologics manufacturing facility for housing its laboratories, production facilities and offices.

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences – and the UMG to enter into a strategic collaboration for the development and commercialization of COVID-19 NanoAbs.

• Health care in Israel
• Science and technology in Israel